News
ACST
--
0.00%
--
Acasti Pharma Announces Review Process of Strategic Alternatives
LAVAL, Québec, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) announces the Company has commenced a formal process to explore and
Benzinga · 09/29 11:03
Acasti announces initiation of strategic alternative process
Acasti Pharma (ACST) has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value.The Company has engaged Oppenheimer as its financial advisor to assist in the
Seekingalpha · 09/29 10:59
Bank-backed stock exchange launches to rival Nasdaq, NYSE
A new exchange backed by Wall Street banks and asset management behemoth BlackRock ([[BLK]] -1.8%) started giving existing stock exchanges a run for their money today.Members Exchange, or MEMX, executed
Seekingalpha · 09/21 19:22
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
LAVAL, Quebec, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the responsibilities
GlobeNewswire · 09/16 10:55
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
LAVAL, Quebec, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the “Circular”) for its upcoming annual and special meeting of shareholders to
GlobeNewswire · 09/11 12:00
The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 11:25
Acasti Pharma Stock Loses a Wall Street Supporter
TipRanks · 09/01 19:10
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
Acasti Pharma downgraded to perform from outperform at Oppenheimer
ACST | Complete Acasti Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/01 11:37
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results
Toward the end of trading Monday, the Dow traded down 0.72% to 28446.24 while the NASDAQ rose 1% to 11,812.92. The S&P also rose, gaining 0.01% to 3,508.25.
Benzinga · 08/31 18:30
Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet
Midway through trading Monday, the Dow traded down 0.94% to 28385.03 while the NASDAQ rose 0.23% to 11722.14. The S&P also fell, dropping 0.33% to 3,496.73.
Benzinga · 08/31 16:04
Acasti Pharma's CaPre flunks late-stage study, shares down 60%
Nano cap Acasti Pharma (ACST) announces unsuccessful results from a second Phase 3 clinical trial, TRILOGY 2, evaluating CaPre (omega-3 phospholipid) for the treatment of patients with very high levels
Seekingalpha · 08/31 13:24
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpointLAVAL, Quebec, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc.  (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical
GlobeNewswire · 08/31 12:00
Acasti Pharma Reports Phase 3 TRILOGY 2 Study Of CaPre Did Not Achieve Statistical Significance For Primary Endpoint
CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint LAVAL, Québec, Aug. 31, 2020 (GLOBE NEWSWIRE) --
Benzinga · 08/31 11:12
What Makes Acasti (ACST) a New Buy Stock
Zacks · 08/14 17:00
Acasti Pharma reports Q1 results
Acasti Pharma (ACST): Q1 GAAP EPS of -C$0.05.Cash and equivalents of C$12.1MShares -1.7% PM.Press Release
Seekingalpha · 08/13 12:44
Acasti Pharma reports Q1 results
Acasti Pharma (ACST): Q1 GAAP EPS of -C$0.05.Cash and equivalents of C$12.1MShares -1.7% PM.Press Release
Seekingalpha · 08/13 12:44
Acasti Pharma reports Q1 results
Acasti Pharma (ACST): Q1 GAAP EPS of -C$0.05.Cash and equivalents of C$12.1MShares -1.7% PM.Press Release
Seekingalpha · 08/13 12:44
Acasti Pharma Q1 EPS $(0.05) vs $(0.11) In Same Qtr. Last Year
Benzinga · 08/13 12:38
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
LAVAL, Quebec, July 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (ome
GlobeNewswire · 07/31 11:55
Webull provides a variety of real-time ACST stock news. You can receive the latest news about Acasti Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ACST
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.
More